Loco-regional recurrence of breast cancer poses significant clinical problems due to frequent inoperability once the chest wall is involved. Early detection of recurrence by molecular imaging agents against therapeutically targetable receptors, such as c-Met, would be of potential benefit. The aim of this study was to assess [ 
INTRODUCTION
The proto-oncogene c-Met is a receptor tyrosine kinase activated by the ligand hepatocyte growth factor (HGF). The HGF/c-Met signaling axis has been described as a promoter of cancer cell growth, angiogenesis, invasion and metastasis (1) . Overexpression of c-Met is associated with poor prognosis and a more malignant tumor phenotype (2, 3) . Several c-Met inhibitors are currently under evaluation in clinical trials, either as stand-alone therapies or in concomitant treatment (4) . c-Met is overexpressed in various solid tumors (5) , including breast cancer (BC), with higher expression in Basal-like Breast Cancer (BLBC) than in other intrinsic cancer subtypes (6) . BLBC, which accounts for up to 15% of all BCs, exhibits a high rate of loco-regional recurrence after initial therapy (7) (8) (9) (10) .
Although treatment of localized disease has improved over the past decades, up to 45% of BC patients suffer a local, regional or systemic relapse within 8 years after initial therapy (8) . While systemic relapse in the form of distant metastasis is still regarded as incurable according to current treatment guidelines, loco-regional recurrence of BC should be treated with curative intention (11) .
Treatment success crucially depends on the earliest possible diagnosis, before chest wall involvement or further organ invasion prevents any form of aggressive treatment (12) . Established guidelines for post-therapy monitoring in BLBC feature mammography and clinical examination which frequently fail to identify local tumor relapse at a sufficiently early stage (13) .
Magnetic resonance imaging (MRI) and FDG-PET/CT offer a comparably higher sensitivity and specificity for detection and characterization of BC relapse (14) . However, differentiation of recurrent BC from inflammatory or infectious processes, and the identification of small lesions (tumor size <20 mm) still impose challenges for FDG-PET (15, 16) . c-Met targeted imaging could provide such a tool to further improve the performance of post-treatment surveillance, and could aid patient stratification for targeted therapy.
For this study we chose the novel, peptide-based molecular imaging agent [ ( Fig 1A) which binds to human c-Met with high affinity (Kd≈2 nM), has a favorable kinetic profile, exhibits specific uptake in c-Met positive tumor tissue and rapid systemic clearance (17). This enables for diagnostic PET imaging as early as one hour after administration (17). The safety, pharmacokinetics and imaging characteristics have all been assessed using GE-137, the fluorescentlabelled analogue of AH113804, in healthy volunteers and in patients at high risk of colorectal neoplasia (17).These initial studies in humans suggested that GE-137 was safe, and that it may improve visualization of colonic polyps, which display a high level for c-Met (17).
In this study, we assessed [
18 F]AH113804-driven PET for the early detection of loco-regional tumor recurrence in a preclinical model of BLBC.
MATERIALS AND METHODS

Cell culture
Human basal-like subtype breast cancer cells HCC1954 (CRL-2338) were obtained from the American Type Culture Collection and cultured in RPMI 1640 (Invitrogen) with 10% fetal calf serum (Bodinco BV) and 2 mM L-glutamine (Invitrogen) at 37 °C in a fully humidified atmosphere containing 5% CO2.
Western blotting
Immunoblotting was performed as described in ref (18) . Detection of bound antibody was with horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence (ThermoScientifc Fisher) with G-Box, Syngene.
Tumor xenograft model
All animal studies were performed in compliance with the UK Home Office Animals (Scientific 
RESULTS
Synthesis of [
18
F]AH113804
Total synthesis time on the automated platform was 49 min. For all synthesis runs, the decay corrected end-of-synthesis yield was between 38 and 41%, with a radioactive concentration (RAC) between 600 and 800 MBq/mL. The radiochemical purity was always >90%, the chemical content between 15 and 20 µg/mL, and specific activity approximately 100 GBq/µmol for each test item.
c-Met expression level in HCC1954
Human c-Met protein expression level was assessed in HCC1954, compared to HT-29 (high c-Met expressing) and U87 (moderate c-Met expressing) cell line lysates. The data shows upregulation of c-Met in the HCC1954 cell line (Suppl Fig 1) . Burggraff et al. assessed the specificity of GE-137, performing a competition study in HT-29 tumor bearing mice which showed a reduction in tumor uptake of GE-137 when co-administrated with an excess of unlabeled peptide (17).
Tumor targeting of [
18
F]AH113804
Baseline uptake of [ 18 F]AH113804 (Fig 1A) was assessed in 8 tumor-bearing animals using PET imaging at 10 days post tumor inoculation (Fig. 1B) . Levels of radioactivity at 60 minutes pi were 4.9±0.6% ID/mL in kidney, 2.9±0.3% ID/mL in liver, and 2.0±0.2% ID/mL in blood. PET imaging ( Fig 1C) Figure 2A ). There was some degree of variation in the uptake of radioactivity at the tumor site in individual animals on each study day (Suppl Table 1 ). However, overall uptake on each day was comparable to that observed in the tumors pre- Fig 6&7) .
Ex vivo histology correlates with the PET images
Following immunofluorescent staining ( Figure 6A ), c-Met expression levels were quantified across whole tumor slides ( Figure 6B Fig 8) .
In addition, it was found that the variation in the c-Met expression levels observed across the tumor samples (displayed in Fig 6B) was due to the tumor size. Indeed, a correlation (r = 0.83; p = 0.0005) was identified between the total c-Met intensity level and the surface area of the tumor sample (Suppl. Fig 9) .
DISCUSSION
Early detection and identification of tumor relapse enables improved loco-regional recurrence control resulting in an increased quality of life and better overall survival for BC patients (20). Current surveillance guidelines have been shown to be less effective in the detection of loco-regional recurrence than the more expensive, yet more sensitive, approaches such as MRI or radionuclide imaging (Single-photon emission computed tomography, PET) (13, 14) . We were able to detect statistically significant differences in tumor uptake compared to contralateral mammary fat pad at Days 6, 13, 20 and 36 after tumor resection. The lack of statistical significance at the latter timepoints is most likely due to the lower, inhomogenous distribution of radioactivity in the tumors. PET images from some of those recurrent tumor bearing animals (images not shown) showed evidence of peripheral uptake only, indicative of necrosis in the tumor core.
Currently 
CONCLUSION
This study demonstrates that [ 
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https The ROI drawn at the tumour site (white arrow) was then replicated at the contralateral mammary fat pad (pink arrow) using the coronal and transverse section. B. ROI volumes for the tumour (t1) and the contralateral site (c1) are very similar. The ROI were drawn manually separately but attention was given to draw similar sized shape ROI for both sites and then checking that the volume of the respective ROI were very similar using the analysis section of the AMIDE software.
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Suppl. Fig. 11 . Identification of an outlier through the fitting of a regression line. to sixteen days after tumor cell implantation, animals underwent surgery for tumor excision, and were subsequently allowed to recover under sufficient analgesia.
The animals were anaesthetized using 2.5% isofluorane in medical oxygen during the surgery. Area of the tumor site was cleaned using povidone-iodine. A 1 cm incision was then made around the tumor. A cotton swab was used to expose the tumor from the mammary fat pad. The tumor was then removed gently and completely from the mammary fat pad using scissors. In some cases, when the tumor was stuck to the skin, the skin was also removed to ensure that there would be no visible remnant of the tumor. Sham surgery was not performed on the contralateral mammary fat pad as the project license would not allow 2 surgeries to take place in one animal.
The animals were monitored for up to 50 days post tumor resection for local tumor recurrence, with PET imaging carried out on selected days post resection (Suppl. (34 mL) from the tC18 cartridge with ethanol (2.4 mL) followed by PBS (2.6 mL) to give the formulated product (total volume 39 mL, ca. 6% EtOH).
CT and PET imaging:
Anesthesia (approximately 2% isoflurane in oxygen) was induced shortly before and 3D ellipsoid ROIs were placed on the tumor in CT images to estimate tumor volume (Suppl Fig 10) . Additional ROIs were placed in skeletal muscle (left forelimb), liver, left and right kidney, and heart (blood pool). All ROI PET data were expressed as decay corrected radioactivity concentration normalized to the injected dose (% ID/mL).
Biodistribution of [ 
Autoradiography:
around each nucleus using an algorithm that identifies stained cytoplasmic and membranous areas.
Raw data included minimum and maximum pixel value for every individual cell within the ROI. The average minimum and maximum pixel values were calculated for the whole region. The obtained data correlated with values acquired from PET scans.
Immunofluorescence:
Tissues were permeabilized and stained similar to the procedure outlined previously (18). A monoclonal rabbit c-Met antibody (1:100, D1C2, Cell signaling), followed by an incubation with a goat anti-rabbit Cy3 secondary antibody (1:500, Sigma), were used. Total fluorescence in each sample was measured and total c-Met-related intensity was corrected for differences between each animal using the same threshold. It was quantified using the software package TRI2 (Paul Barber, Oxford
Institute for Radiation Oncology).
Statistical Analysis:
SEM was calculated to estimate the precision of the sample mean. Paired t-test of logtransformed TMRR was conducted to evaluate the difference between tumor and contralateral mammary fat pad uptake (Fig 2B) . The correlation between total c-Met intensity from frozen tumor samples and the corresponding max %ID/mL for the uptake of [ 18 F]AH113804 at the tumor site ( Fig   6B) is visualized with a scatter plot and Pearson correlation coefficients were calculated. The analysis was restricted to observations which fell between the upper and lower 5 percentile of all residuals, assigning any observation beyond this range as an outlier. This resulted in exclusion of one observation and the remaining seven observations were used in the final analysis (Suppl. Fig. 11 ). A two-sided P-value <0.05 was used to determine significance.
